Wegovy (Semaglutide 2.4 mg) Constipation: Supplements with the Best Evidence

How common is constipation on Wegovy?

In the three pooled placebo-controlled weight-management trials summarised in the Wegovy label — 2,116 adults on 2.4 mg weekly for up to 68 weeks and 1,261 on placebo — constipation was reported by 24% versus 11% [1]. It is one of the most common adverse reactions, behind nausea (44% vs 16%) and diarrhea (30% vs 16%), level with vomiting (24% vs 6%), and ahead of abdominal pain (20% vs 10%) [1]. Overall, 6.8% of people on Wegovy stopped treatment because of an adverse reaction versus 3.2% on placebo, with nausea, vomiting and diarrhea the leading reasons [1].

The rate does not simply track the dose. In the two 72-week trials of the 7.2 mg dose, constipation was reported by 20% on 7.2 mg, 19% on 2.4 mg and 8% on placebo [1]. The label says the 25 mg daily tablet produced reaction types and frequencies similar to the injection [1].

Semaglutide is a GLP-1 receptor agonist, and the label states that it delays gastric emptying [1]. The label does not establish why a particular person develops constipation.

Soluble fiber

The main trial evidence for fiber supplements comes from a systematic review of randomized trials in adults with chronic idiopathic constipation [2]. Six trials met the inclusion criteria — four testing soluble fiber and two testing insoluble fiber — and the authors did not pool the results because of concerns about study quality [2]. Soluble fiber improved global symptoms in 86.5% of people versus 47.4% on placebo, reduced straining in 55.6% versus 28.6%, and raised the mean number of stools per week from 2.9 at baseline to 3.8 after treatment [2]. Evidence for insoluble fiber was conflicting, and the review's authors called for higher-quality trials to establish how well either fiber type works [2].

A review of chronic constipation management in Gastroenterology puts dietary fiber supplementation first, alongside stimulant and osmotic laxatives, before moving to prescription secretagogues or prokinetic agents [6]. The trial numbers above are for soluble fiber as a group, not for one product or dose.

Polyethylene glycol 3350

The 2022 American Gastroenterological Association guideline on irritable bowel syndrome with constipation conditionally recommends polyethylene glycol laxatives, based on low-certainty evidence [3]. That is a weaker endorsement than the same guideline's strong, high-certainty recommendation for linaclotide, a prescription drug [3].

One limit matters here: the guideline population is IBS with constipation, not constipation caused by semaglutide.

Probiotics

A meta-analysis of probiotics pooled 14 randomized trials in 1,182 adults with functional constipation [4]. Probiotics increased stool frequency by 1.3 bowel movements per week (95% CI 0.7 to 1.9) and shortened whole-gut transit time by 12.4 hours (95% CI -22.3 to -2.5 hours), with improved stool consistency [4]. The effect was significant for Bifidobacterium lactis (1.5 bowel movements per week) but not for Lactobacillus casei Shirota [4]. The authors cautioned that heterogeneity and risk of bias were high and called for better-powered trials to settle strain, dose and duration [4].

Does exercise help?

A meta-analysis of nine randomized trials with 680 participants found exercise improved constipation symptoms, with a relative risk of 1.97 (95% CI 1.19 to 3.27) [5]. Eight of the nine trials tested aerobic activity such as walking or qigong [5]. The authors reported high heterogeneity (I-squared 91.3%) and high risk of bias, so the size of any benefit remains uncertain [5].

What the label says about dose escalation

The label's schedule steps the dose every 4 weeks: 0.25 mg for weeks 1 to 4, then 0.5 mg, 1 mg and 1.7 mg in four-week blocks, with maintenance from week 17 at 1.7 mg or 2.4 mg [1]. The Wegovy label states that if a dose is not tolerated during escalation, delaying escalation for 4 weeks can be considered [1].

What the label says to watch for

The label warns about severe gastrointestinal adverse reactions, reported in 4.1% of Wegovy-treated adults versus 0.9% on placebo [1]. Postmarketing reports include ileus, intestinal obstruction and severe constipation with fecal impaction, and the label notes that frequency cannot be estimated from voluntary reports [1]. Wegovy is not recommended in people with severe gastroparesis [1].

The label also lists acute pancreatitis, which can present as persistent severe abdominal pain sometimes radiating to the back, with or without vomiting; it says to discontinue Wegovy if pancreatitis is suspected [1].